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Abstract
Our previous in vitro comparative study on a feline coronavirus (FCoV) pair, differing only in the intactness of their ORF3abc
regions, showed that the truncated ORF3abc plays an important role in the efficient macrophage/monocyte tropism of type
II feline infectious peritonitis virus (FIPV). In the present study, we describe a challenge experiment with the same
recombinant FCoVs in order to gain data on the in vivo characteristics on these viruses. While parent virus FIPV DF-2
developed feline infectious peritonitis in all the infected cats, its recombinant virus PBFIPV-DF-2, differing only in seven
nucleotides, proved to be surprisingly low virulent, although caused an acute febrile episode similarly to the original FIPV
DF-2. PBFIPV-DF-2 infection induced significantly lower virus neutralization titers than its parent virus, and lacked the
second phase of viremia and development of fatal course of the disease. The recombinant PBFIPV-DF-2-R3i with completed
ORF3abc gained biological properties that differentiate between the feline enteric coronavirus (FECV) and FIPV biotypes
such as intensive replication in the gut, absence of viremia and weak or no serological response. Using reverse genetic
approaches our study is the first experimental proof that ORF3abc is indeed responsible for the restriction of FECV
replication to the intestine in vivo.
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Introduction
Feline coronaviruses (FCoVs), members of the Alphacoronavirus
genus within the Coronaviridae family, are major pathogens of Felidae
with worldwide distribution [1]. FCoV occurs in two pathotypes;
feline enteric coronavirus (FECV) primarily replicates in the lower
portion of intestinal tract, spreads by fecal-oral route, and its
clinical appearance is characterized by mild or unapparent
enteritis [2,3]. In contrast, feline infectious peritonitis virus (FIPV)
efficiently replicates in macrophages/monocytes, and can lead to
feline infectious peritonitis (FIP), a highly lethal systemic granu-
lomatous disease, [4–8].
FIPVs arise most likely from FECV in the infected cat via
genetic changes [9]. Characteristic changes can be detected in the
spike (S) gene [10,11], in the ORF7ab [9,12,13] and the ORF3abc
[9,14–16] regions. FECVs have three open reading frames (ORFs)
in the ORF3abc region [6] that code proteins conserved both in
length and sequence in different isolates. On the contrary, the
majority of FIPVs contain genetic alterations (non-synonymous
mutations, deletions and termination codons) mostly in ORF3c
but not rarely in ORF3a and ORF3b [9,14].
The first in vitro comparison of a recombinant FCoV pair
differing only in the intactness of their ORF3abc revealed that
completion of the truncated ORF3abc reduces virus replication
rate by 2log10 titer in feline peripheral blood monocytes [17]
supporting the long time suspected but never experimentally
proved theory that completion of this region alters the in vivo
characteristics and pathogenesis of FCoV [8].
In the present study using the parent FIPV DF-2 strain and its
recombinant derivates we aimed to collect in vivo data how the
completed ORF3abc alters virulence, virus shedding, viremia,
viral load of organs and humoral immune response against type II
FCoV. The data of our experiments show that completion of
ORF3abc vested the highly virulent FIPV DF-2 with properties
that are characteristic to FECV.
Materials and Methods
Cells and Viruses
Felis catus whole fetus 4 (FCWF-4) cells originally purchased
from the American Type Culture Collection were used for virus
propagation, titration and virus neutralization tests. The cell line
was maintained as monolayer culture in Dulbecco’s Modified
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Eagle Medium (Sigma-Aldrich, Saint Louis, MO, USA) supple-
mented with 10% fetal bovine serum (FBS), 0.3 mg/ml glutamine,
100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 mg/ml am-
photericin B, 1 mM sodium pyruvate, and 1% non-essential
amino acids (Sigma-Aldrich). The FIPV DF-2 strain was kindly
provided by Berndt Klingeborn (SVA, Uppsala, Sweden). FIPV
DF-2 is a regular tissue culture adapted strain that has been well
described in the literature, and also used by many other
investigators under this name or as FIPV-79-1146 or FIPV-
Nor15 [16]. Generation of the recombinant PBFIPV-DF-2 and
PBFIPV-DF-2-R3i was described elsewhere [17]. Briefly,
PBFIPV-DF-2 is a virus that originated as a molecular clone of
FIPV DF-2 and then was successfully transfected into cat cells,
where it was replicated for several generations before use in this
study. PBFIPV-DF-2-R3i is a derivate of PBFIPV-DF-2 that was
re-engineered to contain the intact ORF3abc region of canine
coronavirus, and was also transfected into cat cells and cultivated
for several generations before being used in this study.
Sequence Analysis
The complete genome of PBFIPV-DF-2 was reverse transcribed
using the high fidelity SuperScript III First-Strand Synthesis
System (Invitrogen, Carlsbad, CA, USA) and gene-specific
primers. Long PCR fragments overlapping the whole genome
were amplified with Phusion Hot Start High-Fidelity DNA
Polymerase (Finnzymes, Espoo, Finland) and sequenced using
the Ion Proton System (Life Technologies, Carlsbad, CA, USA).
Sequences were aligned and analyzed with the SeqMan Ngen
software (Lasergene, Madison, WI, USA).
Animal Experiments
Specific-pathogen-free IQHsdCpb kittens (Isoquimen SL,
Barcelona, Spain) were used in the challenge experiments. Kittens
arrived at the facility at the age of 8–12 weeks. They were
acclimated and used in the studies at the age of 14–18 weeks. The
animals were kept in separate groups in a closed facility. Their
FCoV negative status was checked with PCR, ELISA and virus
neutralization tests. Kittens were inoculated oronasally with 103
50% tissue culture infective doses (TCID50) of the parent virus
FIPV DF-2 (n = 4) and the recombinant viruses PFIPV-DF-2
(n = 4) and PFIPV-FD-2-R3i (n = 4), respectively. Kittens were
clinically examined on a daily basis for 42 days. Cats were scored
for several clinical signs as described earlier [18]. Briefly, scoring
was based on depression (inactivity for three consecutive days, 1
point), anorexia (not eating for three consecutive days, 1 point),
and neurological disorders (swaggering, 1 point) on a daily basis,
while fever (40.1uC, 1 point), jaundice (yellow plasma, 1 point),
weight loss (loss of 2.5% of body weight per week, 1 point), and
lymphopenia (lymphocyte count of ,0.56109/liter) was scored on
weekly basis. Kittens showing signs of terminal FIP were
euthanized in order to avoid unnecessary suffering, while healthy
animals were exterminated at day 42 postinfection (p.i.), followed
by full postmortem examination. All animal experiments were
approved and supervised by the Ethical and Animal Welfare
Committee of National Food Chain Safety Office (Permission No:
2866/2011). The total number of animals was carefully deter-
mined by considering two main principles: i.) the number of
animals should be ensured proper amount of samples for statistical
analysis and ii.) the 3R rules (Replacement, Reduction and
Refinement) must be implemented.
Detection of Virus Shedding
To determine virus shedding in feces, fecal swabs were collected
at days 0, 7, 14, 21, 28, 35 and 42 p.i., and placed in 500 ml of
phosphate buffered saline (PBS). After vortexing and 30 min
incubation, the swabs were removed, and the extract was
centrifuged at 1000 x g for 10 min to remove cell debris. The
supernatant was used for subsequent PCR.
Viral RNA was purified using the QIAamp Viral RNA Mini Kit
(Qiagen, Hilden Germany). All RNA was stored at -80uC until
used. To measure the copy numbers of the genome and replicative
forms of CoVs, two TaqMan-based quantitative real-time PCR
(qRT-PCR) assays targeting the 59 end of the FIPV DF-2 genome
and the N gene subgenomic (sg) mRNA were applied, respectively
[17]. Each RNA sample was analyzed in duplicates in two
different runs. Differences in original template RNA levels were
normalized by using housekeeping gene b-actin PCR [19]. Means
of the four normalized data per sample were used for further
analysis.
Detection of Viremia
RNA was extracted from whole EDTA anticoagulated blood
taken at days 0, 7, 14, 21, 28, 35 and 42 p.i. using the QIAamp
RNA Blood Mini Kit (Qiagen) according to the manufacturer’s
instructions, and was subjected to genomic and subgenomic qRT-
PCRs.
Viral Load of Organs
To detect virus load in different organs (liver, spleen, kidney,
lung, tonsil, mesenteric lymph nodes, brain and ileum,) approx-
imately 0.5 g pieces of organs diluted in sterile phosphate-buffered
saline (PBS) were homogenized with Tissue Lyser (Qiagen, Hilden,
Germany) to obtain 50% w/v suspension and then were
centrifuged at 1000 x g for 10 min to remove cell debris. RNA
was extracted from the supernatant using the QIAamp Viral RNA
Mini Kit (Qiagen), and was subjected to subsequent genomic and
subgenomic qRT-PCRs.
Serological Assays
Serum samples were taken using VacuetteH tube (Greiner Bio-
One, Germany) at days 0, 7, 14, 21, 28, 35 and 42 p.i. For
antibody ELISA tests, the FCoV EIA Kit, (BV European
Veterinary Laboratory, The Netherlands) was used according to
the recommendations of the manufacturer.
For virus neutralization (VN) assay, two-fold dilutions of heat-
inactivated serum from kittens (50 ml) were incubated for 1 hour at
37uC with equal aliquots of FIPV DF-2 (50 ml of 103.5 TCID50/
ml). The viruses were then added to FCWF-4 cells showing 70%
confluency in a 96-well plate, and incubated for 48 h, until the
development of cytopathic effect. Neutralizing activity was
determined by end-point dilution [20].
Statistical Analysis
To determine the statistically significant difference between the
VN titers generated after inoculation with the three FCoVs, the
unpaired two-tailed Student T test with equal variances was
applied. The p value under 0.05 was considered as a statistically
significant difference.
Results
Virulence of Recombinant Viruses
Cats inoculated with the parent virus FIPV-DF-2 showed rapid
development of FIP at day 10–16 p.i. The animals exhibited
depression and anorexia, in most cases with fever, jaundice, weight
loss and lymphopenia, and they had to be euthanized between
days 21–25 (Table 1). Pathological examinations proved the
characteristic lesions of effusive FIP with multiple dispersed
In Vivo Analysis of FIPV DF-2 Recombinants
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pyogranulomas in the abdominal organs such as livers, spleens and
kidneys.
Surprisingly, cats challenged with PBFIPV-DF-2, a recombi-
nant FCoV containing truncated ORF3abc like the parent virus,
showed only clinical signs of the acute phase of the disease,
including transient fever from day 3 to 8, anorexia and slight
lymphopenia (Table 1). All cats fully recovered and survived until
termination of the experiment (day 42 p.i.). Macroscopically no
lesions were observed in these animals.
Cats inoculated with PBFIPV-DF-2-R3i, the recombinant
FCoV containing complemented ORF3abc, showed neither any
clinical signs typical of FIP nor diarrhea (Table 1). All cats
survived, and showed no macroscopic lesions except for slight
enlargement of mesenteric lymph nodes in two animals.
In order to elucidate the unexpected low-virulent phenotype of
PBFIPV-DF-2, the full-length genomic sequence of the virion was
determined using next generation sequencing, and data revealed
that besides the 1-nucleotid (nt) change at position 24429 (G/A)
that resulted in an amino acid (aa) change in the fusion domain of
S protein at position 1332 (V/I) and the 1-nt silent mutation at
position 26064 (T/C) in the M gene found also in the infectious
clone [17], additional mutations are present in the viral genome.
In the ORF1ab gene, three nucleotide substitutions were found at
positions 3098 (A/G), 5241 (G/A) and 7632 (C/T) resulting in aa
changes at positions 930 (T/A), 1644 (G/D) and 2441 (S/L)
affecting non-structural proteins (nsps) 3 and 4. Furthermore, a
single nt change was present at position 27817 (C/G) affecting the
last nucleotide of ORF 7 transcription regulatory sequence (TRS),
and a 1-nt substitution also occurred at position 28492 (G/C)
causing an amino acid change at position 121 (K/N) in the 7b
protein. The possible role of mutation of the TRS of ORF7 in
decreased ORF7 mRNA transcription was examined by an
ORF7-specific subgenomic qRT-PCR assay, and similar sub-
genomic ORF7 mRNA levels were detected after inoculating
FCWF cells with the wild type and recombinant FCoVs,
indicating no effect of this mutation to mRNA transcription (data
not shown). The genome of PBFIPV-DF-2-R3i contained only the
point mutations observed in the infectious clone.
Virus Shedding
Shedding of FIPV DF-2 and PBFIPV-DF-2 was detected from
day 3 p.i. to euthanasia of the PIP diseased animals at very low and
variable amounts of an average value close to the detection limit of
the genomic qRT-PCR (1.96101 FCoV RNA copies per ml fecal
extract) (Fig. 1) with undetectable virus replication using the
subgenomic qRT-PCR assay (data not shown). Virus shedding
decreased to undetectable levels from day 21 p.i. in the PBFIPV
inoculated animals.
The PBFIPV-DF-2-R3i infected cats began to shed the virus
from day 3 p.i., virus shedding peaked at day 7 p.i. with 8.36105
FCoV RNA copies per ml fecal extract, remained high until day 14
p.i., then began to decrease until reaching 1.26102 FCoV RNA
copies per ml fecal extract at day 35 p.i., and remained at this level
until the end of the experiment (Fig. 1).
FCoV Viremia
A classic biphasic viremia was observed in FIPV DF-2 infected
cats. FCoV RNA was detected from day 3 p.i., reached a first peak
of 4.86103 FCoV RNA copies per ml blood by day 7 p.i., then
decreased quickly after the emergence of neutralizing antibodies.
A second wave of viremia was detected from day 14 p.i. until death
peaking at 5.86104 FCoV RNA copies per ml blood (Fig. 2).
The PBFIPV-DF-2 infected cats developed only the first phase
of viremia, FCoV RNA was detected in blood from day 3 p.i.,
reached a peak of 16103 FCoV RNA copies per ml blood by dy 7
p.i., and decreased to undetectable level at day 21 (Fig. 2).
In cats inoculated with PBFIPV-DF-2-R3i, complete absence of
viremia was observed, the presence of FCoV genomic RNA in
Table 1. Total clinical scores of cats challenged oronasally with the parent virus FIPV DF-2 (n = 4) and recombinant FCoVs PBFIPV-
DF-2 (n = 4) and PBFIPV-DF-2-R3i (n = 4).
Virus and
animal no. Clinical score
Total
clinical
score
Day of death
postinfection
Fever Depression Anorexia Jaundice
Neurological
disorder Weight loss Lymphopenia
FIPV DF-2
1 2 2 2 3 1 3 2 15 21
2 2 2 2 3 0 2 2 13 25
3 2 3 3 3 1 3 2 17 21
4 2 2 2 3 1 2 2 14 22
PBFIPV- DF-2
5 1 1 1 0 0 1 1 5 –
6 1 1 1 0 0 1 1 5 –
7 1 1 0 0 0 0 0 2 –
8 1 1 1 0 0 0 1 4 –
PBFIPV-DF-2-R3i
9 0 0 0 0 0 0 0 0 –
10 0 0 0 0 0 0 0 0 –
11 0 0 0 0 0 0 0 0 –
12 0 0 0 0 0 0 0 0 –
doi:10.1371/journal.pone.0088758.t001
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blood was not detected until the termination of the experiment
(Fig. 2).
FCoV Viral Load in Tissues
Cats infected with FIPV DF-2 showed high viral load (4.66104–
1.26107 genomic RNA copies per g tissue) in the examined organs
with intensive virus replication but very limited RNA copy
numbers (1.16102 genomic RNA copies per g tissue) were
obtained from the gut (Fig. 3). In cats infected with PBFIPV-
DF-2, no detectable FCoV RNA copies were found in the
examined organs.
The PBFIPV-DF-2-R3i challenged animals tested highly
positive (3.66104 genomic RNA copies per g tissue) for FCoV
RNA in the ileum. In addition, significantly lower level of
positivity was observed in the mesenteric lymph node of two cats
(36102 genomic RNA copies per g tissue) (Fig. 3). No other organs
contained genomic RNA. The subgenomic qRT-PCR showed
replication only in the gut.
High copy number (.103) genomic qRT-PCR results were
confirmed with subgenomic qRT-PCR assay not only from organs
but all fecal and blood samples (data not shown).
Humoral Immune Response
According to the pre-experimental data, no FCoV antibodies
were detected at day 0 p.i. in any cat sera using ELISA and VN. In
the FIPV DF-2 inoculated animals, neutralizing antibodies
appeared by day 10 p.i., and reached high titers (2.46103) at
the time of euthanasia (Fig. 4).
The PBFIPV-DF-2 challenged cats developed neutralizing
antibodies from day 10 p.i. that elevated to lower levels
(6.46102) by day 35 p.i. than in the FIPV DF-2 inoculated
animals (Fig. 4). The difference between VN titers generated after
FIPV DF-2 and PBFIPV-DF-2 was statistically significant
(p = 0.037).
The PBFIPV-DF-2-R3i infected cats showed variable results. As
ELISA and VN assays showed, two animals did not seroconvert
(data not shown). Two animals seroconverted by day 14 p.i., and
their VN titers remained at low levels (9.66101) compared with
those of the PBFIPV-DF-2 infected cats (Fig. 4). The difference
between VN titers generated after PBFIPV-DF-2 and PBFIPV-
DF-2-R3i was statistically significant (p = 0.013).
Discussion
The distinctive factor of the different pathogenesis of the two
FCoV biotypes is the increased macrophage tropism of FIPV
[10,21], while FECV is tropic for the mature intestinal epithelium
[22,23]. Although alterations of several different genes of FCoV
are suspected in the background of phenotypic characteristics, the
most widely accepted theory suggests the possible role of the
truncated ORF3abc in the altered tropism and consequent
pathogenesis of the two biotypes [9,14,16,18,24]. However, an
identical FCoV pair differing only in the intactness of ORF3abc
has not been tested yet in vivo due to the lack of a cell culture for
propagation of type I FECV and a ‘‘true’’ type II FECV isolate
[8]. Our previous in vitro experiments added further evidence to
the involvement of truncated ORF3abc to the increased macro-
phage tropism of type II FCoV [17]. In the present study,
characterizing the parent FIPV DF-2 and the recombinant FCoV
pair in in vivo experiments, we were able to distinguish significant
differences in their biological properties.
Development of typical clinical signs and post mortem lesions of
classical FIP were observed in cats infected with the parent virus
FIPV DF-2 similarly as it was reported earlier [5,18,25].
Unexpectedly, kittens inoculated with PBFIPV-DF-2 showed only
the acute phase of the disease with similar tropism as its wild-type
parent FIPV DF-2. Sequencing of the pBFIPV-DF-2 infectious
clone [17] and the recovered virus PBFIPV-DF-2 that was
passaged in FCWF three times revealed point mutations originat-
ed in two waves during cloning (24429 (G/A) and 26064 (T/C))
and passaging (3098 (A/G), 5241 (G/A),7632 (C/T), 27817 (C/G)
and 28492 (G/C)).
One of the two aa substitutions affecting nsp3 was found in
papain-like protease 2 responsible for proteolytic processing of
Figure 1. Fecal shedding of FCoV by cats challenged oronasally
with the parent virus FIPV DF-2 and recombinant FCoVs
PBFIPV-DF-2 (n=4) and PBFIPV-DF-2-R3i (n =4), as monitored
with genomic qRT-PCR. The means of groups are given. Error bars
represent standard deviations.
doi:10.1371/journal.pone.0088758.g001
Figure 2. FCoV viraemia of cats challenged oronasally with the
parent virus FIPV DF-2 (n=4) and recombinant FCoVs PBFIPV-
DF-2(n=4) and PBFIPV-DF-2-R3i (n=4), as monitored with
genomic qRT-PCR. The means of groups are given. Error bars
represent standard deviations.
doi:10.1371/journal.pone.0088758.g002
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nsp1 and nsp2 [26], proteins with functions of host gene
expression inhibition [27] and cellular signaling disruption [28].
One hydrophobic amino acid change (V to I) was identified
close to the second heptad repeat in the interhelical region of S2
fusion domain of S protein responsible for virus-mediated
membrane fusion. Similar conservative (M to L) aa substitution
is suspected to be responsible for attenuation of of type I FCoV
close to the first heptad repeat in this protein [11].
A nucleotide substitution found in the genome of PBFIPV-DF-2
affected the TRS of ORF7 gene. Mutations in TRS of
transmissible gastroenteritis virus (TGEV) were shown not to alter
virus replication in vitro [29]. Accordingly, in our in vitro experi-
ments, no difference was found between the replication dynamics
of the parent strain and the recombinant virus [17], and ORF7
mRNA transcription was found equal after both FIPV DF-2 and
PBFIPV-DF-2 infection.
The 7b protein is considered as one of the virulence factors of
FIPV [13,18,30,31]. However, several FIPVs have lost virulence
upon tissue culture passage do not have 7b mutations. A large
number of FIPV and FECV genomes in GenBank also confirm
that mutations in 7b are not associated with the FIP mutation.
Considering that the exact biological function of this protein is
unknown, and no single aa mutation in 7b was reported which
alter virulence of FCoV, the role of the aa substitution (K/N)
found in the 7b protein of PBFIPV-DF-2 is most likely has no
effect on the virulence of this cloned virus.
The difference in virulence could be the consequence of any or
combination of the point mutations in the genome of the
recombinant FCoV obtained from the infectious clone [17] and
during the three passages on FCWF after transfection and virus
recovery. Similar problems with the attenuation of a virulent type I
FCoV after bacterial cloning have been also reported by others
[32]. A transient fever is often seen during the first few days after
infection with virulent FIPVs, probably due to early host/virus
interactions, but actual disease signs of FIP only occur when
antibodies start to appear. The aforementioned mutations could
lead to less effective replication of PBFIPV-DF-2 in macrophages/
monocytes in vivo, or this mutated FCoV was not reacting in the
same manner with antibodies as its wild type counterpart.
The low and inconsistent level of fecal shedding following
inoculation with the parent FIPV DF-2 strain and the recombi-
nant PFIPV-DF-2 containing truncated ORF3 is similar to that of
previous observations [14,24]. A classic biphasic viremia detected
in FIPV DF-2 infected cats was similar to earlier experiments using
the genetically closest FIPV strain 79–1146 [5]. As it was suspected
from clinical signs, viremia was different in PBFIPV-DF-2
challenged animals. The infection kinetics of the two viruses was
similar in the first days of infection, with the first replication peak
at day 7 p.i. (Fig. 2), confirming our previous in vitro data obtained
from feline blood monocytes [17], although the titer of PBFIPV-
DF-2 was almost one log lower at the day of peak, and decreased
rapidly. Seroconversion also started at the same time in the FIPV
DF-2 and PBFIPV-DF-2 inoculated animals but remained at
lower level in the latter case until the end of the experiment. These
data indicate self-limiting replication of PBFIPV-DF-2 and
complete clearance by the immune system that was further
confirmed by the absence of the genomic RNA in the organs
(Fig. 3).
The differences between the biological properties of the two
viruses with truncated ORF3abc are substantial but by far less
pronounced than it can be observed between the ORF3abc
deleted and ORF3abc completed FCoVs. PBFIPV-DF-2-R3i
genome was invariably absent in the blood monocytes. As a
possible consequence of the absence of viremia, viral load of
organs was not detected, the presence of PBFIPV-DF-2-R3i was
found only in the mesenteric lymph node of two animals that
showed weak seroconversion. These data indicate rather carrier
role of macrophages/monocytes of FCoV with completed
ORF3abc from the sites of the intensive FCoV replication. The
absence of replication in blood monocytes of PBFIPV-DF-2-R3i
inoculated cats coincide with previous data collected after FECV
infection studies [3,22,23,33], which clearly demonstrated the
limited replication of the FECVs in mononuclear cells [5,34].
The weak or missing seroconversion of PBFIPV-DF-2-R3i
challenged cats is an obvious explanation of the low or absent
systemic replication of the virus, and it is comparable with
previous experimental type I FECV infections that showed low
and often variable antibody titers in serum or plasma
Figure 3. FCoV load of organs of cats challenged oronasally
with the parent virus FIPV DF-2 (n=4) and recombinant FCoVs
PBFIPV-DF-2 (n=4) and PBFIPV-DF-2-R3i (n =4), as monitored
with genomic qRT-PCR. The means of groups are given. Error bars
represent standard deviations.
doi:10.1371/journal.pone.0088758.g003
Figure 4. Induction of FCoV-neutralizing antibodies after
oronasal challenge of cats with the parent virus FIPV DF-2
(n=4) and recombinant FCoVs PBFIPV-DF-2(n=4) and PBFIPV-
DF-2-R3i (n =4). The means of groups are given. Error bars represent
standard deviations.
doi:10.1371/journal.pone.0088758.g004
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[22,23,35,36], while a proportion of cats remained seronegative
despite intensive fecal virus shedding [22].
Indeed, intensive fecal shedding and virus replication was
detected during the whole period of the experiment and from the
ileum of the sacrificed cats challenged with PBFIPV-DF-2-R3i
carrying completed ORF3abc, in contrast to the other two
investigated viruses. Our results are in accordance with the classic
theory that mutations (deletions and nonsense mutations) altering
the number and size of proteins translated from ORF3abc
contribute to the altered tissue tropism of FIPV. This theory was
reinforced by genetic investigations [24] that revealed that non-
deleted ORF3abc of FIPVs accumulates four times more unique
non-synonymous amino acid mutations in the ORF3abc than the
FECVs, possibly modifying the biological function of these
proteins.
Data of PBFIPV-DF-2-R3i shedding in the present study are
similar with those of acute FECV and enteric CCoV infection.
Recent experiments [32] with recombinant type II FIPV showed
that ORF3c containing stop codon can be restored to code full-
length 3c protein by point mutation during replication in internal
organs and the gut. To investigate the mutability of this region we
sequenced the 3c region of PBFIPV-DF-2-R3i from fecal and
intestinal samples and we found no genetic alterations in this
region (data not shown).
In type I FECV challenge studies [23,35,37,38] FCoVs with
intact ORF3abc shed at significantly higher titers compared with
FIPVs, allowing horizontal spread to contact animals. The type II
FCoVs used in our challenge studies are the result of double
recombination between type I FCoV and type II CCoV [39]. In
this respect, results of the present study are also in accordance with
CCoV shedding pattern gained from canine experimental
infection [40].
Summarizing the results of our challenge experiment, and
comparing with previous experimental and clinical data, we
conclude that the ORF3abc truncated recombinant virus showed
attenuated phenotype with low virulence, transient viremia and
complete clearance of the virus. Therefore, we cannot draw clear
conclusion on the role of truncation of ORF3abc in the
development of FIPV pathogenesis, although the biological
properties of PBFIPV-DF-2 were closer to attenuated FIPV than
to those of FECV. However, completion of ORF3abc vested
PBFIPV-DF-2-R3i with biological properties that differentiate
between the FECV and FIPV biotypes, such as intensive
replication in the gut, absence of viremia and weak or no
serological response.
The observation of numerous natural and experimental FCoV
infection in the past decades led to the rise of the idea that
completed ORF3abc is indispensable for intestinal replication of
the virus. However, this theory has never been confirmed due to
the lack of an identical virus pair differing only in their ORF3abc
regions. Using such a virus pair our study is the first experimental
proof which confirms the decisive role of ORF3abc in the
intestinal replication of FCoV.
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